| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/JM0109614 |
| P698 | PubMed publication ID | 11831890 |
| P50 | author | Barbara Cacciari | Q114403516 |
| Stefano Moro | Q37828926 | ||
| Karl-Norbert Klotz | Q42882153 | ||
| Giorgia Pastorin | Q47316874 | ||
| Giampiero Spalluto | Q92485723 | ||
| P2093 | author name string | Tatiana Da Ros | |
| Pier Giovanni Baraldi | |||
| Katia Varani | |||
| Pier Andrea Borea | |||
| Stefania Gessi | |||
| P2860 | cites work | Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats | Q34871163 |
| Molecular modeling studies of human A3 adenosine antagonists: structural homology and receptor docking | Q40989540 | ||
| Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. | Q47829073 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 770-780 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists | |
| P478 | volume | 45 |
| Q39418010 | A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy |
| Q36342540 | Chapter 13. A3 Adenosine Receptors |
| Q34313641 | Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety |
| Q44554593 | Exploring the molecular basis of selectivity in A1 adenosine receptors agonists: a case study |
| Q28279556 | Highlights on the development of A(2A) adenosine receptor agonists and antagonists |
| Q59489014 | Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists |
| Q34490693 | Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists |
| Q35545074 | Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships |
| Q37135506 | Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile |
| Q43049495 | Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes |
| Q36092094 | Quality Issues with Public Domain Chemogenomics Data. |
| Q40647461 | Recent developments in the field of A2A and A3 adenosine receptor antagonists |
| Q59171613 | Recent developments in the field of A3 adenosine receptor antagonists |
| Q28252689 | Structure-affinity relationships of adenosine A2B receptor ligands |
| Q46417110 | Synthesis and antimicrobial activity of some new pyrazole, fused pyrazolo[3,4-d]-pyrimidine and pyrazolo[4,3-e][1,2,4]-triazolo[1,5-c]pyrimidine derivatives |
| Q36626953 | Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility |
| Q35020369 | Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process |
| Q37957791 | The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches |
| Q34313795 | The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors |
| Q37967933 | Update 1 of: Computational Modeling Approaches to Structure–Function Analysis of G Protein-Coupled Receptors |
| Q35059150 | Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo |
Search more.